Navigation Links
LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase
Date:4/30/2008

BURLINGTON, Mass., April 30 /PRNewswire-FirstCall/ -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of peripheral vascular devices and implants, today announced financial results for Q1 2008. Q1 2008 revenues were $11.8 million, an increase of 20% over Q1 2007.

Q1 2008 revenues increased 5% in the Company's endovascular and dialysis access category and 31% in its vascular category, while general surgery revenues decreased 4%. Strong performance from newly acquired products and core open vascular surgery devices drove revenue in the quarter, as did the weak dollar.

The Company reported a gross margin of 71.7% in Q1 2008 versus 74.6% in the year-earlier quarter. While the Company continued to drive manufacturing efficiencies at its Massachusetts plant, the Q1 margin decrease resulted from Biomateriali sales and strong international sales. Biomateriali was acquired in December and sells through an exclusive distributor. International sales, with lower selling prices, accounted for a record 46% of the Company's Q1 revenues.

George W. LeMaitre, Chairman and CEO said, "Our revenues are diversified by both product and geography. This continued to serve us well in 2008, and I'm pleased to report 20% sales growth for the quarter. Growth was driven by strong sales from our 2007 acquisitions and from our core open vascular devices. I'm also pleased to report that our UNITE stent graft clinical trial has gathered some momentum and now has 13 operational sites and 12 enrollees."

The Q1 2008 operating loss was $2.6 million. During the quarter the Company recorded $1.1 million of three previously disclosed special charges: the Sorin write-down, the reduction in force ("RIF"), and the Italian distributor non-compete. Excl
'/>"/>

SOURCE LeMaitre Vascular, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. LeMaitre Vascular to Participate in 28th Annual Cowen and Company Health Care Conference
2. LeMaitre Vascular Acquires Biomateriali, a Vascular Graft Manufacturer
3. LeMaitre Vascular Appoints Russell D. Hays to Its Board of Directors
4. Cardium Reports on Science Channel Series Featuring InnerCools Endovascular Cooling During Brain Surgery at Stanford University
5. CardioVascular BioTherapeutics, Inc. Funding Wound Healing Trial with R&D Partnership
6. CardioVascular BioTherapeutics, Inc. Announces Update on Timing of Form 10-K Filing
7. Angiotech elects to suspend Vascular Wrap(TM) pivotal clinical trials
8. ES Vascular Receives CE Mark for its First Aortic Stapler for End-to-End Anastomosis Between Synthetic Grafts and Aorta During Open Repair of Aortic Aneurysmal and Occlusive Disease
9. BRISTOL-MYERS SQUIBB SELECTS ISIS DRUG TARGETING PCSK9 AS DEVELOPMENT CANDIDATE FOR PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE
10. Significant Reductions in Mortality and Cardiovascular Events Shown Using Blood Pressure-Lowering Treatment in Those Aged 80 and Over
11. Boston Scientific Announces Sale of TriVascular Endovascular Aortic Repair Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... A new look at “big glass” ... trends will highlight technical sessions at SPIE Photomask ... its 33rd year, the three-day event is the industry’s ... suppliers, approximately 100 technical presentations and numerous networking lunches ... for optics and photonics , the meeting will be ...
(Date:6/18/2013)... million electric cars could be on roads across North America ... research by the United States Department of Energy, Los Alamos ... Chen is part of a team led by the Los ... the expensive platinum catalysts in fuel cells. , "One of ... vehicles is the cost of the units. The pure platinum ...
(Date:6/18/2013)... June 18, 2013 The Regulatory ... of two new offices in Asia—one in Singapore and ... serve as RAPS’ Pan-Asia office , serving the ... more focused on audiences within China. , The announcement ... partnership with five Singapore government agencies to develop and ...
(Date:6/18/2013)... Phoenix, AZ (PRWEB) June 18, 2013 ... the 2013 Innovation Challenge Winner out of hundreds of ... in its spring Arizona Innovation Challenge . The ... the country for a technology commercialization challenge, granting a ... world’s most promising technology ventures. Nasseo’s state of the ...
Breaking Biology Technology:‘Big Glass’ and Visions for the Future are on the Program for SPIE Photomask Technology 2‘Big Glass’ and Visions for the Future are on the Program for SPIE Photomask Technology 3US and Canadian researchers drive towards cheaper fuel cells for electric cars 2RAPS Opens Offices in Singapore and China 2RAPS Opens Offices in Singapore and China 3Nasseo Named 2013 Innovation Challenge Winner by Arizona Commerce Authority 2
... OAKS, Calif., Dec. 11 Ceres, Inc. announced today,that ... under its,Blade Energy Crops label. The highly anticipated launch ... specifically as raw materials,for biofuels and biopower. The company ... The company reported ...
... 11 Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today ... Directors, unexpectedly passed away on Wednesday. Dr. Waltz had been ... At the time of his death, Dr. Waltz served on ... , "The sudden loss of our ...
... CARY, N.C., Dec. 11 Cornerstone Therapeutics Inc. ... company focused on developing and commercializing prescription medications ... the status of its integration activities following the ... Inc. and Cornerstone BioPharma Holdings, Inc. on October ...
Cached Biology Technology:First Seed Sales of Dedicated Energy Crops Begin 2First Seed Sales of Dedicated Energy Crops Begin 3Peregrine Pharmaceuticals Mourns Loss of Chairman Thomas A. Waltz 2Cornerstone Therapeutics Provides Update on Integration Activities and Issues 2008 Revenue Guidance 2Cornerstone Therapeutics Provides Update on Integration Activities and Issues 2008 Revenue Guidance 3Cornerstone Therapeutics Provides Update on Integration Activities and Issues 2008 Revenue Guidance 4Cornerstone Therapeutics Provides Update on Integration Activities and Issues 2008 Revenue Guidance 5
(Date:6/18/2013)... very large "dead zone" in the Gulf of Mexico ... Chesapeake Bay this year, based on several NOAA-supported forecast ... Louisiana State University, and the Louisiana Universities Marine ... hypoxic "dead" zone will be between 7,286 and 8,561 ... largest recorded. That would range from an area the ...
(Date:6/18/2013)... awarded $12.7 million to match nine academic research ... to explore new treatments for patients in eight ... and schizophrenia. The collaborative pilot initiative, called Discovering ... by the National Center for Advancing Translational Sciences ... , The process of developing a new therapeutic ...
(Date:6/18/2013)... Molecular Pathology is proud to announce it will join ... on July 1, 2013. The FASEB Board approved AMP,s ... The 26 constituent societies of FASEB represent more than ... advancement of research and education in biological and biomedical ... now than ever," said Jennifer L. Hunt, MD, MEd, ...
Breaking Biology News(10 mins):NOAA, partners predict possible record-setting deadzone for Gulf of Mexico 2NOAA, partners predict possible record-setting deadzone for Gulf of Mexico 3NOAA, partners predict possible record-setting deadzone for Gulf of Mexico 4NIH to fund collaborations with industry to identify new uses for existing compounds 2NIH to fund collaborations with industry to identify new uses for existing compounds 3NIH to fund collaborations with industry to identify new uses for existing compounds 4
... 1, 2011 JERUSALEM, Israel EUREKA the ... supported by 40 member states and mobilizing more than ... today announced the launch of "E!nnoVest", its new ... This web-based instrument allows investors to identify highly-qualified and ...
... DALLAS June 1, 2011 A drug already ... a therapy for a common form of dementia, UT ... acid (SAHA) holds promise as a first-generation drug for ... a progressive, inherited neurodegenerative disease for which there is ...
... Plant Biologists (ASPB) has named the recipients of its 2011 ... program assists promising undergraduate students so they can conduct meaningful ... a key element of the program, and a solid mentoring ... work with a mentor who is an ASPB member. ...
Cached Biology News:Cancer drug holds promise as first treatment for common, inherited dementia 2ASPB awards 15 summer undergraduate research fellowships 2ASPB awards 15 summer undergraduate research fellowships 3ASPB awards 15 summer undergraduate research fellowships 4
... antibody development to targets including proteins and ... and cancer-specific surface antigens. A&Gs service ... completed in approximately 40 days (duration may ... antigens). Phase I: Immunization, test bleed ...
... ZMD.368. Immunogen: Synthetic peptide derived ... human WNT2B/WNT13 protein. Specificity: Specific ... and rat WNT2B/WNT13 proteins. Recognizes both ... Reactivity: Mouse Human Rat (positive controls: ...
... Synthetic peptide derived from the N-terminal ... 17 open reading frame 37 (C17orf37 protein) ... C35 protein. On Western blots it identifies ... Reactivity: Human (positive control: full-length human ...
...
Biology Products: